Butterfly Network, Inc. (BFLY)

Current Report Filed: 2026-05-08

Dr. Erica Schwartz's contingent resignation as director pending CDC confirmation introduces uncertainty around board composition, though her departure would only occur upon Senate confirmation of her nomination by President Trump on April 16, 2026.
The Board expanded from seven to eight directors with the appointment of Caroll H. Neubauer on May 18, 2026, bringing fresh independent oversight with positions on the Compensation and Technology committees.
Mr. Neubauer will receive standard nonemployee director compensation including $300,000 in RSUs vesting over three years, representing routine equity incentive alignment with other board members and no special arrangements.
No material conflicts of interest or related-party transactions were identified with the new director, and the Board confirmed his independence under NYSE listing standards, maintaining governance compliance.

Insider Trading Filed: 2026-05-05

CAO and SVP of Finance Megan Carlson sold 110,422 shares on May 1, 2026 at a weighted average price of $4.749, representing a significant insider sale by a senior finance executive.
Post-transaction, Carlson retains 507,209 shares of beneficial ownership, indicating she maintains substantial equity stake despite the sale and did not completely divest her position.
The sale occurred at relatively depressed price levels ($4.735-$4.785 range), suggesting either opportunistic selling during a weak period or potential concerns about near-term stock performance by a key finance officer.
As CAO and SVP of Finance, this insider's sale may signal reduced confidence in the company's financial trajectory or valuation at current levels, warranting investor scrutiny of recent financial performance.

Insider Trading Filed: 2026-05-01

Chief Business Officer Steve Cashman sold 147,518 shares on April 29, 2026, at an average price of $4.909 per share, generating approximately $724,000 in proceeds through an automatic 'sell-to-cover' tax withholding policy rather than a discretionary sale.
Following the transaction, Cashman retains direct beneficial ownership of 2,029,868 Class A Common Stock shares, indicating substantial continued confidence in the company despite the tax-driven sale.
The sale price range of $4.82-$5.125 per share reflects a relatively narrow trading band, suggesting modest stock volatility during the transaction execution period.
This is a routine equity transaction tied to restricted stock unit vesting rather than a strategic insider position change, as the company's 'sell-to-cover' policy automatically executes sales to fund tax obligations.

Current Report Filed: 2026-04-30

Butterfly Network announced Q1 2026 results on April 30, 2026, providing investors with early-year financial performance and operational updates that will be key to assessing momentum in the medical imaging device market.
The filing was signed by CFO John Doherty, indicating standard financial disclosure procedures without indication of material adverse events or extraordinary transactions requiring executive-level involvement.
The press release is furnished as non-filed exhibit material, meaning it carries limited regulatory liability but provides transparency on business performance and forward-looking guidance that shareholders will scrutinize for revenue trends and profitability trajectory.

Quarterly Report Filed: 2026-04-30

The filing is dated April 30, 2026 for Q1 2026 (ended March 31, 2026), indicating the company is operating and filing regularly with the SEC for the medical device sector.
The XBRL metadata shows detailed segment tracking including Product revenue, Software and Other Services segments, with geographic breakdowns (US and Non-US), suggesting diversified revenue streams across multiple business lines.
The document references dual-class common stock structure (Class A and Class B), multiple warrant types (public and private), and RSU/stock option equity instruments, indicating a complex capital structure typical of post-SPAC merger companies.
Presence of customer concentration risk disclosures and inventory valuation tracking suggests the company manages customer dependencies and manufacturing operations, which are typical operational risks for early-stage medical device companies.

Insider Trading Filed: 2026-04-17

Steve Cashman, the Chief Business Officer of Butterfly Network, Inc. (BFLY), sold 200,000 shares of Class A Common Stock on April 16, 2026 under a Rule 10b5-1 trading plan.
The shares were sold at a weighted average price of $5.222 per share, with prices ranging from $5.00 to $5.610 per share.
Cashman's remaining beneficial ownership in BFLY is 2,177,386 shares, indicating he still holds a significant position in the company.

Insider Trading Filed: 2026-03-06